Introduction
============

Female infertility is a complex disorder which may be caused by medical conditions including pelvic inflammatory disease, endometriosis, Polycystic Ovary Syndrome (PCOS), premature ovarian failure and uterine fibroids ^[@B1]^. PCOS is a heterogeneous female endocrine metabolic disorder affecting 5--10% of women characterized by its significantly complex clinical alignments ^[@B2]^. Endometriosis is a chronic, benign, estrogen-dependent condition characterized by the presence of endometrial tissue outside the uterus cavity associated with pelvic pain and infertility. The pathophysiologic mechanism of endometriosis is unknown and it affects 3--10% of women in reproductive years of their life and 20--50% of women with infertility ^[@B3]--[@B5]^. In fact, PCOS and endometriosis appear to have a complex and multifactorial etiology in which a variety of genes interact with environmental factors to produce these conditions. Recent biochemical and genetic studies on the pathogenesis of PCOS and endometriosis were focused on the Single Nucleotide Polymorphisms (SNPs) affecting Oxidative Stress (OS) ^[@B6],[@B7]^. The results of these studies suggest that genetic polymorphisms in antioxidant genes including the SNPs affecting the activities of paraoxonase 1 (PON1) may contribute to female infertility ^[@B8]^. Serum paraoxonase 1 is an antioxidant calcium-dependent esterase/lactonase, which circulates within High Density Lipoprotein (HDL) particles ^[@B9],[@B10]^. PON1 possesses antioxidant, anti-atherogenic, and anti-inflammatory properties and is involved in hydrolysis of several organophosphorus insecticides and nerve agents, inhibition of Low Density Lipoprotein (LDL) oxidation and increase of macrophage-associated cholesterol efflux ^[@B11]^. The activities of PON1 are genetically regulated and the *PON1* gene polymorphisms have potent influences on its activities. PON1 is a member of a multigene cluster including *PON1*, *PON2*, and *PON3* ^[@B12]^. Among all the SNPs of *PON1* gene, −909G/C \[rs854572\], −162A/G \[rs705381\], −108C/T \[rs705379\] in the promoter region and Q192R \[rs662\], L55M \[rs-854560\] in the coding region are the most studied polymorphisms ^[@B13],[@B14]^. The L55M polymorphism influences the paraoxonase and arylesterase (ARE) activities and the stability of the protein ^[@B15]^. In this case-control study, PONase and AREase activities were examined and the association of coding L55M polymorphism with female infertility in Iranian population was investigated. The L55M polymorphism could be a risk factor in determining susceptibility to female infertility.

Materials and Methods
=====================

Subjects
--------

This case-control study analyzed a group of 50 infertile females including 20 with endometriosis who were diagnosed by laparoscopy and 30 with PCOS fulfilling the criteria for PCOS ^[@B16]^, who attended the Isfahan Fertility-Infertility Center and Royan Institute. The control group consisted of 70 healthy age-matched volunteers who visited the clinic for a regular health check-up with proven fertility and no clinical or biochemical hyperandrogenism, no menstrual cycle irregularities, and no history of endometriosis and PCOS. Women from different regions of Iran were referred to this infertility center for check-up and they made the population of this study. There was no evidence of known paraoxonase-affecting diseases such as CHD, liver diseases, atherosclerosis, diabetes, hypertension, cancer and infections in all fertile and infertile females who were not genetically related. Blood sampling was done based on patient consent and an agreement was signed between the University of Isfahan and Isfahan Fertility-Infertility Center. Blood samples were obtained in the morning after overnight fasting and collected in EDTA and heparin coated tubes to analyze *PON1 L55M* polymorphism and PON1 activities. Blood and serum samples were stored at −20*°C* until analysis.

Genotyping analyses
-------------------

For genotype analysis, genomic DNA was extracted from peripheral blood using a salting-out method described by Miller ^[@B17]^ and was stored at −20*°C* till genotyping could be performed. Coding L55M (rs 854560) genotyping was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The primers for SNP were designed using the primer design software Oligo 7 and were listed as follows: Forward primer: 5′ TGAATTATTCTGAACCTATTA AAGAAGA 3′Reverse primer: 5′ AAGACTTAAACTGCCAGTCCT AGA 3′

PCR was performed in 25 *μl* reaction mixture containing 2 *μl* of each forward and reverse primers (10 *pM*), 2.5 *μl* of ×10 solution buffer (20 *mM* Tris-HCl pH=8.6, 50 *mM* KCl, Cinnagen Inc, Iran), 0.5 *μl* of four mixed dNTPs (10 *mM*, Cinnagen Inc, Iran), 0.75 *μl* of Mgcl2 (50 *mM*, Cinnagen Inc, Iran), 0.3 *μl* of 5*u/μl* Taq DNA polymerase (Cinnagene, Co., Iran), and 2 *μl* (100 *ng/μl*) of genomic DNA. The PCR program was as follows: initial denaturation for 4 *min* at 94*°C* followed by 35 cycles of 40 *s* at 94*°C*, 35 *s* at 54--66*°C*, 72*°C* for 40 *s*, and a final extension step of 15 *min* at 72*°C*. The PCR products were run on 2% agarose gel and were visualized by ethidium bromide staining. Moreover, a restriction analysis was performed using 10 units of *Hin*1II enzyme (Fermentas, Vilnius, Lithuania) in buffer G (Fermentas) at 37°*C* for 16 *hr*. The restriction fragments were analyzed on 2% agarose gels and were visualized through ethidium bromide staining. Digested DNA fragments of 146 and 103 *bp* were detected in MM homozygotes (restriction site present), an undigested band of 249 *bp* was detected in LL homozygotes (restriction site absent) and heterozygous genotypes resulted in three different bands (146, 103 and 249 *bp*) through PCR-RFLP technique ([Figure 1](#F1){ref-type="fig"}).

![Electrophoresis pattern of *PON1 L55M* polymorphism using PCR-RFLP and *Hin*1II restriction enzyme. I) Undigested PCR products, II) LM (103,146, and 249 *bp* fragments). III to VII) MM (103, and 146 *bp* fragments), LL (249 *bp* fragment), LL, and LM genotype, respectively. M) 100 *bp* ladder. Numbers are in base pair (*pb*).](AJMB-7-173-g001){#F1}

Analyses of PON1 activities
---------------------------

The serum was isolated by centrifugation at 800 *g* for 10 *min* at 4*°C* and was immediately frozen at −80*°C* in order to determine PON1 activities in blood samples. The PONase activity was measured using paraoxon (Sigma Chem, USA) as substrate and the increase in absorbance at 412 *nm* was determined, because of 4 -nitrophenol formation. The activity was measured at 25*°C* during 3 *min* after 5 *μl* of serum were added to each well containing 100 *μl* of Tris/HCl (100 *mMol*, pH=8.0) buffer including 2 *mMol* CaCl~2~ and 5.5 *mMol* of paraoxon. All results are expressed in *U/ml* which is defined as 1 *nmol* of 4- nitrophenol formed per minute. Arilesterase activity in serum was determined spectrophotometrically using the phenylacetate (Merck-Schardt) as a synthetic substrate. The reaction started by adding 100 *μl* of phenylacetate (10 *mM*) as substrate solution to wells containing 5 *μl* of serum (prediluted 1:10) and 1 *mM* CaCl~2~ (Sigma, USA) in 50 *mM* Tris buffer pH=8. The phenol production was measured during 2 *min* at 270 *nm* and pH=8.0. The PON1's arilesterase activity is expressed as *KU/ml* which is defined as 1 *μmol* arilesterase per minute. PON1's paraoxonase and arilesterase activities were determined in triplicate ^[@B18]^.

Briefly, serum PON1 activity (PON1 phenotype) was determined by double substrate method. Phenotype is defined as the activity ratio of PONase activity divided by AREase activity.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA) software. The Chi-square distribution (*χ^2^*) was used to evaluate the PON1 genotype frequencies between the patient and the control groups. Multiple comparisons were done by employing one way analysis of variance (ANOVA) followed by a LSD (least significant difference) test. All data are presented as means ± standard deviation (SD). Statistical significance was assessed using the 5% significance level.

Results
=======

Distribution of PON1 L55M genotype
----------------------------------

The association between *PON1 L55M* polymorphism and female infertility in case and control subjects is shown in [table 1](#T1){ref-type="table"}. The distribution of genotypes were in Hardy-Weinberg equilibrium (p = 0.45). The results showed that there were significant differences regarding *PON1 L55M* polymorphism among fertile and infertile groups. The women with a MM genotype (p=0.021; OR=2.55) were statistically associated with infertility in comparison to those with a LM genotype (p=0.039; OR=1.91). There was no association between L55M polymorphism and each infertile group including patients with endometriosis and PCOS separately.

###### 

Association between *PON1 L55M* polymorphism and female infertility

  **1^st^ Polymorphism**   **2^nd^ Polymorphism**   **1^st^ and 2^nd^ mean difference**           **Standard deviation**   **p-value**
  ------------------------ ------------------------ --------------------------------------------- ------------------------ -------------
  **MM**                                                                                                                   
                           LM                       0.23214 [^\*^](#TFN1){ref-type="table-fn"}    0.09928                  0.021
                           LL                       −0.02381                                      0.12924                  0.854
  **LM**                                                                                                                   
                           MM                       −0.23214 [^\*^](#TFN1){ref-type="table-fn"}   0.09928                  0.021
                           LL                       −0.25595 [^\*^](#TFN1){ref-type="table-fn"}   0.12272                  0.039
  **LL**                                                                                                                   
                           MM                       −0.02381                                      0.09928                  0.854
                           LM                       0.25595 [^\*^](#TFN1){ref-type="table-fn"}    0.12924                  0.039

Significance difference with 95% confidence interval.

PONase, AREase activities and infertility
-----------------------------------------

The group mean age, body mass index (BMI), and the serum PON1's paraoxonase and arilesterase activities are presented in [table 2](#T2){ref-type="table"} for fertile, PCOs, and endometriosis groups. Paraoxonase enzyme activity was highly variable among different samples. According to LSD test, endometriosis subjects had significantly lower paraoxonase enzyme activity compared to control groups (p=0.0024; CI=95%) ([Table 3](#T3){ref-type="table"}). No significant difference was found in women with PCOS for both PONase and AREase activity in comparison with control group (p=0.469; CI=95%).

###### 

Characteristics of cases and control samples (mean±SD)

                                       **PCOS**          **Endometriosis**   **Fertile**
  ------------------------------------ ----------------- ------------------- -----------------
  **Age**                              31.92±4.38        31.54±6.212         32.09±6.56
  **Body Mass Index (BMI)**            28.03±5.41        24.89±4.02          24.66±3.86
  **Paraoxonase activity (*U/l*)**     1682.88±2255.47   1259.90±1680.95     2529.02±3144.78
  **Arilesterase activity (*KU/l*)**   227.67±131.11     212.88±119.79       255.58±145.53
  **Serum PON1 activity**              7.39±6.89         5.91±6.78           9.89±5.71

###### 

Association between infertility and paraoxonase enzyme activity

  **Group 1**         **Group 2**     **Mean difference between two groups**        **Standard deviation**   **p-value**
  ------------------- --------------- --------------------------------------------- ------------------------ -------------
  **Endometriosis**                                                                                          
                      Fertile         −3.86913 [^\*^](#TFN2){ref-type="table-fn"}   1.68803                  0.024
                      PCO             −1.14816                                      1.58038                  0.469
  **Fertile**                                                                                                
                      Endometriosis   4.86913 [^\*^](#TFN2){ref-type="table-fn"}    1.68803                  0.024
                      PCO             2.72097                                       2.01152                  0.179
  **PCO**                                                                                                    
                      Endometriosis   1.14816                                       1.58038                  0.469
                      Fertile         −2.72097                                      2.01157                  0.179

Significance difference with 95% confidence interval.

Association between PON1 L55M polymorphism and serum PON1 activities
--------------------------------------------------------------------

The association of *PON1 L55M* polymorphism with PON1 activities is shown in [figure 2](#F2){ref-type="fig"}. Significant difference was observed among the genotypes of L55M polymorphism in patient and control groups. Serum PON1 activity was the highest in LL genotype followed by LM and then MM genotype (MM\<LM\<LL) in both patients and controls. It was found that in three genotypes, patients had significantly lower activity in comparison with controls.

![L55M genotypes (LL, LM and MM) and serum PON1 activity in both controls and patients. Serum PON1 activity was the highest in LL genotype followed by LM and then MM genotype (MM\<LM\<LL) in both patients and controls.](AJMB-7-173-g002){#F2}

Discussion
==========

Serum PON1 is a esterase/lactonase which has significant roles in protection of LDL and HDL against oxidation ^[@B19]--[@B23]^. Recently, PON1 genotyping and analysis of serum PON1 activity has been comprehensively studied to investigate associations with variety of diseases including cardiovascular disease, diabetes, infertility, Alzheimer, cancer, and Parkinson ^[@B20]--[@B24]^. Genetic variants in *PON1* gene may modulate OS and thus affect susceptibility to female infertility. OS which was defined as imbalance between pro-oxidants and antioxidants has critical roles in normal functioning of the female reproductive system and development of female reproductive diseases such as endometriosis, and PCOS ^[@B25],[@B26]^. The effects of OS on male infertility have been well described, but its impacts on female reproductive disorders are generally unknown. In this case-control study, PON1 enzyme activities (PONase and AREase), and *PON1 L55M* coding polymorphism were investigated in Iranian infertile women population for the first time. The global minor allele frequency of *PON1 L55M* polymorphism (rs854560) is T=0.1827/915 according to the dSNP ([www.ncbi.nlm.nih.gov/snp](www.ncbi.nlm.nih.gov/snp)). This means that for rs854560, minor allele is 'T' and has a frequency of 18.27% in the 1000 genome phase 1 population. It was found that serum PON1 activity was significantly lower in endometriosis patients in comparison with controls. This result is similar to previous studies which have been performed in different populations ^[@B27],[@B28]^. In another study, Verit *et al* reported a significant difference in two groups of endometriosis patients including women with moderate to severe endometriosis and women with minimal to mild endometriosis. PON-1 activity was significantly lower in women with moderate to severe endometriosis than in women with minimal to mild endometriosis and controls (p\<0.0001) ^[@B29]^. The association between PON1 activity and PCOS was suggested by Dursun *et al* for the first time. They reported a significant difference (p=0.027) in PON1 activity between PCOS patients and control groups ^[@B30]^. In the present study, there was no significant difference in serum PON1 activity of PCOS patients in comparison with the control group. The association of *PON1 L55M* polymorphism and PON1 activity was also evaluated in our study which indicated that PON1 activity was affected by L55M polymorphism. PONase activity was the highest in LL genotype and lowest in MM genotype in both patients and control groups (p=0.002; CI=95%) and in all the three genotypes (LL, LM, MM); patients had lower PONase activity in comparison with controls. PON's activity varies widely between individuals and is related to several other environmental factors. Our further analyses indicate that AREase activity was independent of L55M polymorphism which is similar to the observation by Chen *et al* ^[@B31]^. Briefly, serum PON1 activity or PON1 phenotype was the highest in LL genotype followed by LM and then MM genotype (MM\<LM\< LL) in both patients and controls. In addition, it was found that MM genotype was more common in infertile females as compared to the controls (OR=2.55; p=0.021; *χ^[@B2]^* significance=0.029) and LM genotype was associated with low risk of infertility (OR=1.91; p= 0.039) ([Table 4](#T4){ref-type="table"}). Furthermore, it was observed that the frequencies of *PON1 L55M* polymorphism in this Iranian population were similar to those for European Caucasians but different from those seen in other Asian populations ^[@B32]^. The findings of a case-control study which was performed by Sepehrvand *et al* confirmed this similarity of *PON1 L55M* polymorphism frequency in other Iranian population ^[@B33],[@B34]^.

###### 

Distribution of *PON1 L55M* genotypes in fertile and infertile groups

  **Genotype**   **Fertile, N^[a](#TFN3){ref-type="table-fn"}^** **(f)**   **Infertile, N (f** **[^b^](#TFN4){ref-type="table-fn"})**   **OR** **[^c^](#TFN5){ref-type="table-fn"}** **(CI** **^d^** **95%)**   **p-value**
  -------------- --------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------- -------------
  **LL**         20 (28.6)                                                 20 (40)                                                                                                                              
  **LM**         40 (57.2)                                                 15 (30)                                                      1.91                                                                    0.039
  **MM**         10 (14.28)                                                15 (30)                                                      2.55                                                                    0.021
  **Total**      70                                                        50                                                                                                                                   

Number;

Frequency;

Odd ratio.

Conclusion
==========

In conclusion, results of this study support the hypothesis that *PON1 L55M* polymorphism may have significant roles in serum PON1 activity and risk of developing female infertility. Our findings suggest further analyses are required to investigate other PON1 polymorphisms and their importance on the individual's susceptibility to infertility in larger groups.
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